Search Results 741-750 of 17021 for monoclonal antibody

1. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.

2. Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

   ... monoclonal antibody and an immunomodulatory drug. * Must be naïve to treatment with ABBV-383. Exclusion Criteria: - Received B-cell maturation antigen (BCMA) ...

3. A Study to Evaluate Budesonide in Patients with Immune Mediated Enteropathies - Mayo Clinic

   ... monoclonal antibodies, alpha-4 beta-7 integrin inhibiting monoclonal antibody, interleukin 12/23 inhibiting monoclonal antibody, JAK inhibitors.

4. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Any previous treatment with anti-CD19 antibody, complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody * ...

5. Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody (mAb). - Must be naïve to treatment with B-cell maturation antigen (BCMA)-targeted therapy. - Must be eligible to receive the ...

6. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

   Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...

7. A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache - Mayo Clinic

   Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody ... Known hypersensitivity to multiple drugs, monoclonal antibodies or ...

8. Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients - Mayo Clinic

   Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) ...

9. A Study to Evaluate ADP-A2M4 with Pembrolizumab to Treat Recurrent or Metastatic Head and Neck Cancer - Mayo Clinic

   ... monoclonal antibody. History of autoimmune or immune mediated disease prior to enrollment. Subjects with hypothyroidism, diabetes, adrenal insufficiency or ...

10. A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia - Mayo Clinic

    History of clinically significant hypersensitivity associated with monoclonal antibody therapies. 3. Personal history of venous or arterial thrombosis or ...